Why the study?
Do serum ADMA, nitrate, vitamin B12, and homocysteine levels predict the development of chronic thromboembolic pulmonary hypertension in patients with pulmonary embolism?
Do serum ADMA, nitrate, vitamin B12, and homocysteine levels predict the development of chronic thromboembolic pulmonary hypertension in patients with pulmonary embolism?
Serum ADMA, nitrate, vitamin B12, and homocysteine levels do not appear to predict the development of chronic thromboembolic pulmonary hypertension in patients with pulmonary embolism.
Answers are grounded in this paper and cite their sources.
These biomarkers should not inform CTEPH risk assessment after PE; leaves open identification of alternative predictors in prospective cohorts.
We aimed to analyze the pre- and posttreatment serum asymmetric dimethylarginine (ADMA), nitrate (NO(3)), vitamin B(12) and homocysteine levels in pulmonary embolism (PTE) patients and to determine the prognostic value of these variables in predicting chronic thromboembolic pulmonary hypertension (CTEPH). This study was conducted in 64 patients. The patients were classified into the two groups: patients with normal pulmonary artery pressure (PAP) (group I) and patients with high PAP with persistent lung perfusion defects or who died at the end of 3 months of therapy (group II). We found statistically significant differences between two groups with respect to the partial oxygen pressure, the oxygen saturation, and the PAP, but there was no difference between the two groups with respect to the pretreatment ADMA, NO(3), or homocysteine levels. The vitamin B(12) levels were higher in group II. The NO(3) levels increased and the ADMA and vitamin B(12) levels decreased with treatment in both groups. These results suggest that these parameters are not predictive of the development of CTEPH.
No takes yet. Share an insight, caveat, or question.
Altuntaş et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: